Alpha Tau Medical Ltd. (DRTS)
| Market Cap | 425.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.27M |
| Shares Out | 68.48M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,050 |
| Open | 6.94 |
| Previous Close | 6.94 |
| Day's Range | 6.15 - 7.63 |
| 52-Week Range | 4.68 - 20.65 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 19.89 (+219.8%) |
| Earnings Date | Jun 27, 2022 |
About DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for DRTS stock is "Buy." The 12-month stock price forecast is 19.89, which is an increase of 219.77% from the latest price.
News
Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update
JERUSALEM, March 28, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...
12 Stocks Halted On A Circuit Breaker This Week
A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and brin...
Why Alpha Tau Medical Stock Skyrocketed Today
The stock enjoyed another big gain.
Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of Business Combination
JERUSALEM and WILMINGTON, Del., March 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd.
Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in ...
JERUSALEM, Jan. 20, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has signed a sponsored ...
Healthcare Capital Corp Announces Special Meeting Date for Proposed Business Combination with Alpha Tau Medical Ltd.
NEW YORK, New York and JERUSALEM, Israel, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp (NASDAQ: HCCC, HCCCW, and HCCCU) (“HCCC”) today announced that on January 12, 2022, the U.S. Securitie...
Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer
JERUSALEM, Jan. 3, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by Hek...
Alpha Tau Announces Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)
JERUSALEM, Nov. 3, 2021 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that it has enrolled its first pa...
Alpha Tau Announces Completion of Enrollment in First US Clinical Trial of Alpha DaRT™ and Achievement of First Prima...
JERUSALEM, Oct. 25, 2021 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that its US pilot trial for skin...
Alpha Tau and Healthcare Capital Corp. to Combine and Create A Publicly Traded Company Focused on Transforming the Tr...
- Alpha Tau's proprietary Alpha DaRT™ is designed to deliver uniquely potent alpha radiation to destroy solid tumors with localized precision, sparing surrounding healthy tissue, thereby maintaining can...